(Q38030974)

27 August 2017

title

The role of tocilizumab in the management of rheumatoid arthritis (English)

1 reference

27 August 2017

1 reference

1 reference

2

Paul Emery

0 references

author name string

Zoe Ash

series ordinal

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

31 July 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

9

1 reference

27 August 2017

page(s)

1277-1289

1 reference

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Interleukin-6: discovery of a pleiotropic cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Molecular cloning and expression of an IL-6 signal transducer, gp130

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R down-regulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Constitutive production of interleukin-6 and immunologic features in cardiac myxomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Total cholesterol and LDL levels decrease before rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Analysis of C-reactive protein levels and febrile tendency after joint surgery in rheumatoid arthritis patients treated with a perioperative 4-week interruption of tocilizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Tocilizumab in refractory adult Still's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.707178

10.1517/14712598.2012.707178

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1067588650

0 references

Fatcat ID

release_qfok2u3xpvdwdab3f7akbwqy3a

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qfok2u3xpvdwdab3f7akbwqy3a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference